IDEAYA Biosciences, Inc. Comprehensive Income
IDEAYA Biosciences, Inc. (IDYA) reported Comprehensive Income of -$113.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-04
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$113.63M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$101.30M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$83.06M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $119.78M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$112.24M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$274.23M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$109.53M.
- IDEAYA Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$60.81M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$113.63M 10-Q · filed 2026-08-04 | -$214.93M 10-Q · filed 2026-08-04 | -$297.99M derived: sum of 3 quarters · filed 2026-08-04 | -$178.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$101.30M 10-Q · filed 2026-05-05 | -$184.36M derived: sum of 2 quarters · filed 2026-05-05 | -$64.58M derived: sum of 3 quarters · filed 2026-05-05 | -$142.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$83.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $36.72M derived: sum of 2 quarters · filed 2026-02-17 | -$40.84M derived: sum of 3 quarters · filed 2026-08-04 | -$112.24M 10-K · filed 2026-02-17 |
| 2025-09-30 | $119.78M 10-Q · filed 2025-11-04 | $42.22M derived: sum of 2 quarters · filed 2026-08-04 | -$29.18M 10-Q · filed 2025-11-04 | -$162.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$77.56M 10-Q · filed 2026-08-04 | -$148.96M 10-Q · filed 2026-08-04 | -$282.30M derived: sum of 3 quarters · filed 2026-08-04 | -$328.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$71.41M 10-Q · filed 2026-05-05 | -$204.74M derived: sum of 2 quarters · filed 2026-05-05 | -$251.31M derived: sum of 3 quarters · filed 2026-05-05 | -$304.57M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$133.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$179.91M derived: sum of 2 quarters · filed 2026-02-17 | -$233.17M derived: sum of 3 quarters · filed 2026-02-17 | -$274.23M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$46.57M 10-Q · filed 2025-11-04 | -$99.83M derived: sum of 2 quarters · filed 2025-11-04 | -$140.89M 10-Q · filed 2025-11-04 | -$173.53M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$53.27M 10-Q · filed 2025-08-05 | -$94.32M 10-Q · filed 2025-08-05 | -$126.97M derived: sum of 3 quarters · filed 2026-02-17 | -$153.98M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$41.06M 10-Q · filed 2025-05-06 | -$73.70M derived: sum of 2 quarters · filed 2026-02-17 | -$100.71M derived: sum of 3 quarters · filed 2026-02-17 | -$128.41M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | -$32.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$59.65M derived: sum of 2 quarters · filed 2026-02-17 | -$87.35M derived: sum of 3 quarters · filed 2026-02-17 | -$109.53M 10-K · filed 2026-02-17 |
| 2023-09-30 | -$27.01M 10-Q · filed 2024-11-04 | -$54.71M derived: sum of 2 quarters · filed 2024-11-04 | -$76.89M 10-Q · filed 2024-11-04 | -$99.95M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$27.70M 10-Q · filed 2024-08-06 | -$49.87M 10-Q · filed 2024-08-06 | -$72.94M derived: sum of 3 quarters · filed 2025-02-18 | -$71.70M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$22.17M 10-Q · filed 2024-05-07 | -$45.24M derived: sum of 2 quarters · filed 2025-02-18 | -$44.00M derived: sum of 3 quarters · filed 2025-02-18 | -$66.88M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$23.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$21.83M derived: sum of 2 quarters · filed 2025-02-18 | -$44.71M derived: sum of 3 quarters · filed 2025-02-18 | -$60.81M 10-K · filed 2025-02-18 |
| 2022-09-30 | $1.24M 10-Q · filed 2023-11-07 | -$21.64M derived: sum of 2 quarters · filed 2023-11-07 | -$37.74M 10-Q · filed 2023-11-07 | -$56.62M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$22.88M 10-Q · filed 2023-08-10 | -$38.99M 10-Q · filed 2023-08-10 | -$57.86M derived: sum of 3 quarters · filed 2024-02-20 | -$69.49M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$16.11M 10-Q · filed 2023-05-09 | -$34.98M derived: sum of 2 quarters · filed 2024-02-20 | -$46.61M derived: sum of 3 quarters · filed 2024-02-20 | -$57.56M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$18.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$30.50M derived: sum of 2 quarters · filed 2024-02-20 | -$41.45M derived: sum of 3 quarters · filed 2024-02-20 | -$50.48M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$11.63M 10-Q · filed 2022-11-08 | -$22.58M derived: sum of 2 quarters · filed 2022-11-08 | -$31.61M 10-Q · filed 2022-11-08 | -$36.77M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$10.95M 10-Q · filed 2022-08-15 | -$19.98M 10-Q · filed 2022-08-15 | -$25.14M derived: sum of 3 quarters · filed 2023-03-07 | -$30.09M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$9.03M 10-Q · filed 2022-05-10 | -$14.19M derived: sum of 2 quarters · filed 2023-03-07 | -$19.14M derived: sum of 3 quarters · filed 2023-03-07 | -$31.47M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$10.11M derived: sum of 2 quarters · filed 2023-03-07 | -$22.45M derived: sum of 3 quarters · filed 2023-03-07 | -$34.55M 10-K · filed 2023-03-07 |
| 2020-09-30 | -$4.95M 10-Q · filed 2021-11-15 | -$17.28M derived: sum of 2 quarters · filed 2021-11-15 | -$29.39M 10-Q · filed 2021-11-15 | -$40.18M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | -$12.33M 10-Q · filed 2021-08-10 | -$24.44M 10-Q · filed 2021-08-10 | -$35.24M derived: sum of 3 quarters · filed 2022-03-18 | -$46.16M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | -$12.11M 10-Q · filed 2021-05-10 | -$22.90M derived: sum of 2 quarters · filed 2022-03-18 | -$33.83M derived: sum of 3 quarters · filed 2022-03-18 | -$44.46M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | -$10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$21.72M derived: sum of 2 quarters · filed 2022-03-18 | -$32.35M derived: sum of 3 quarters · filed 2022-03-18 | -$41.88M 10-K · filed 2022-03-18 |
| 2019-09-30 | -$10.93M 10-Q · filed 2020-11-12 | -$21.55M derived: sum of 2 quarters · filed 2020-11-12 | -$31.09M 10-Q · filed 2020-11-12 | -$39.66M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | -$10.63M 10-Q · filed 2020-08-12 | -$20.16M 10-Q · filed 2020-08-12 | -$28.73M derived: sum of 3 quarters · filed 2021-03-23 | -$41.77M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | -$9.53M 10-Q · filed 2020-05-12 | -$18.11M derived: sum of 2 quarters · filed 2021-03-23 | -$31.14M derived: sum of 3 quarters · filed 2021-03-23 | -$38.14M derived: sum of 4 quarters · filed 2021-03-23 |
| 2018-12-31 | -$8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$21.61M derived: sum of 2 quarters · filed 2021-03-23 | -$28.61M derived: sum of 3 quarters · filed 2021-03-23 | -$34.38M 10-K · filed 2021-03-23 |
| 2018-09-30 | -$13.04M 10-Q · filed 2019-11-13 | -$20.04M derived: sum of 2 quarters · filed 2019-11-13 | -$25.80M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$7.00M 10-Q · filed 2019-08-12 | -$12.76M 10-Q · filed 2019-08-12 | ||
| 2017-12-31 | -$11.86M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |